Dyadic's C1 Platform Selected By The Vaccine And Immunotherapy Center At Massachusetts General Hospital As Part Of VIC's $5.88M Award By U.S. DoD To Develop A Self-Assembling Vaccine Platform For Rapid Production Of Prophylactic Vaccines
Portfolio Pulse from Benzinga Newsdesk
Dyadic International (NASDAQ:DYAI) has entered into a research collaboration agreement with the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital and Voltron Therapeutics. The collaboration is part of a $5.88 million award from the U.S. Department of Defense to VIC for the development of a Self-Assembling Vaccine (SAV) Platform for rapid production of prophylactic vaccines. Dyadic's proprietary C1 protein production platform will be used to express vaccine antigens for influenza A and other infectious diseases. If successful, this collaboration could provide a commercial opportunity for Dyadic to receive revenues from products brought to market.
October 05, 2023 | 12:42 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Dyadic's partnership with VIC and Voltron Therapeutics could lead to the development of a rapid vaccine production platform. If successful, this could provide a commercial opportunity for Dyadic to receive revenues from products brought to market.
The news of Dyadic's partnership with VIC and Voltron Therapeutics is highly relevant as it directly involves the company's proprietary technology. The potential success of this project could lead to significant revenues for Dyadic, positively impacting its stock price. However, the project's success is not guaranteed, hence the confidence score is not at the maximum.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100